Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902198 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HTTGAAL3MBTL1 | |
| SCHEMBL12436958 | 0.80 | POLB (0.44) | ALDH1A1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL14490929 | 0.79 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AHTTGAA | |
| SCHEMBL6436721 | 0.79 | EPHX2 (0.43) | ALDH1A1RAB9AL3MBTL1GLAPDE4B | |
| SCHEMBL12436979 | 0.77 | ALDH1A1 (0.47) | ALDH1A1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL6436720 | 0.77 | EPHX2 (0.42) | ALDH1A1RAB9AL3MBTL1GLAPDE4B | |
| SCHEMBL12436920 | 0.77 | GAA (0.46) | ALDH1A1SMN1; SMN2RAB9AGAANPC1 | |
| SCHEMBL12436034 | 0.77 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2GAAL3MBTL1NPC1 | |
| SCHEMBL12436953 | 0.77 | EPHX2 (0.50) | ALDH1A1GAANPC1 | |
| SCHEMBL15183940 | 0.77 | ATM (0.48) | ALDH1A1SMN1; SMN2RAB9AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ALDH1A1 1615/4885SMN1; SMN2 4696/4885RAB9A 2841/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ALDH1A1 1584/4885SMN1; SMN2 4624/4885RAB9A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.